Search company, investor...

Bayhill Therapeutics

bayhilltherapeutics.com

Founded Year

2000

Stage

Dead | Dead

Total Raised

$97.35M

About Bayhill Therapeutics

Bayhill Therapeutics Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapeutics that fundamentally alter the way autoimmune diseases are treated. The company has developed two therapeutic platforms with broad applicability to a range of autoimmune diseases. Bayhill's BHT-DNA autoimmune vaccine is designed to eliminate disease-causing cells without effecting normal protective immune system cells. BHT-DNA is being studied in a Phase II trial for multiple sclerosis and a Phase I/II trial for autoimmune diabetes. Bayhill's second therapeutic is an oligonucleotide in preclinical development for systemic lupus erythematosus.

Headquarters Location

1810 Gateway Drive Suite 150

San Mateo, California, 94404,

United States

650-320-2800

Missing: Bayhill Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Bayhill Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Bayhill Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Bayhill Therapeutics is included in 1 Expert Collection, including Diabetes.

D

Diabetes

1,898 items

Bayhill Therapeutics Patents

Bayhill Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/21/2003

10/12/2010

Cannabinoids, Inflammations, Designer drugs, Indoles, Clusters of differentiation

Grant

Application Date

11/21/2003

Grant Date

10/12/2010

Title

Related Topics

Cannabinoids, Inflammations, Designer drugs, Indoles, Clusters of differentiation

Status

Grant

Bayhill Therapeutics Frequently Asked Questions (FAQ)

  • When was Bayhill Therapeutics founded?

    Bayhill Therapeutics was founded in 2000.

  • Where is Bayhill Therapeutics's headquarters?

    Bayhill Therapeutics's headquarters is located at 1810 Gateway Drive, San Mateo.

  • What is Bayhill Therapeutics's latest funding round?

    Bayhill Therapeutics's latest funding round is Dead.

  • How much did Bayhill Therapeutics raise?

    Bayhill Therapeutics raised a total of $97.35M.

  • Who are the investors of Bayhill Therapeutics?

    Investors of Bayhill Therapeutics include Latterell Venture Partners, U.S. Venture Partners, Morgenthaler Ventures, Presidio Partners, The Vertical Group and 10 more.

  • Who are Bayhill Therapeutics's competitors?

    Competitors of Bayhill Therapeutics include La Jolla Pharmaceutical Company, Apitope, Endocyte, Biosceptre International, Decimmune Therapeutics and 15 more.

Compare Bayhill Therapeutics to Competitors

REGiMMUNE Logo
REGiMMUNE

REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.

S
Stem Cells Bank

Stem Cells Bank Biotechnological Company engaged in development of autovaccines for treating oncological diseases and tuberculosis, produced on the basis of autologous dendritic cells (cells extracted from the organism of the very patient to be given the vaccine). In the framework of thus project it is planned to develop and launch a vaccine for treating oncological diseases and tuberculosis, produced on the basis of cells extracted from the organism of the very patient to be given the vaccine.

A
American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

D
Dare Bioscience

Dare Bioscience is a healthcare company committed to the development and commercialization of innovative products in women's reproductive health. We believe there is an unmet need globally for new product candidates that expand options, improve outcomes and are easy to use. By advancing these products, we seek to expand choices and to make a difference in the lives of women worldwide.

L
LeukoSight

LeukoSight Inc. is an early stage biotechnology company developing a line of therapeutics that can be used to treat autoimmune and inflammatory diseases.

Cellerant Therapeutics Logo
Cellerant Therapeutics

Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.